Results 151 to 160 of about 9,895 (222)

Model-informed safety management of tocilizumab for pediatric sJIA: a PBPK approach for dose-escalation and vaccination timing. [PDF]

Front Immunol
Yang Y, Wang R, Li Z, Zheng L, Shen C.
europepmc   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
wiley   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Leveraging [¹⁸F]F-Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer. [PDF]

Clin Transl Sci
van der Gaag S, Veerman MJC, Yilmaz H, Amsu J, Pruijn SJV, Oprea-Lager DE, Cysouw MCF, Jansen BHE, Yaqub MM, Vis AN, Hendrikse H, Bartelink IH.   +11 more
europepmc   +1 more source

Physiologically based pharmacokinetic modeling and dose adjustment of imipenem in pediatric patients with renal impairment. [PDF]

Front Cell Infect Microbiol
Feng C, Xiao P, Qu Y, Fan K, Wang Y, Zhang X, Wang X, Pan J, Deng Y, Yu Y.   +9 more
europepmc   +1 more source

Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically-Based Pharmacokinetic Approach. [PDF]

CPT Pharmacometrics Syst Pharmacol
McKnite AM, Hamadeh A, Hunt JP, Green DJ, Imburgia C, Whelan A, Hudson R, Chevalier A, Mathis CL, Yang MJ, Dwyer JP, Edginton A, Watt KM.   +12 more
europepmc   +1 more source

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment. [PDF]

Front Pharmacol
Pokladyuk A, Voronova V, Helmlinger G, Peskov K, Kosinsky Y.   +4 more
europepmc   +1 more source

Pharmacometric modeling of opioid disposition in pregnancy: a systematic review of PopPK and PBPK approaches, model limitations, and future directions. [PDF]

Front Pharmacol
Zaidi SS, Abbasi MY, Ganapaneni S, Quinney SK.   +3 more
europepmc   +1 more source

Developmental age and clinical illness drive <i>in vivo</i> variability of CYP1A2 ontogeny and caffeine metabolism in preterm neonates. [PDF]

Front Pharmacol
Wang MC, Sealey VA, Rahman M, Ngugama M, Trolat A, Wybenga-Groot L, Moran MF, Dinh J, Lewis TR.   +8 more
europepmc   +1 more source

Physiologically-Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach. [PDF]

Clin Transl Sci
Khier S, El Gaaloul M, Tarning J, Abla N.   +3 more
europepmc   +1 more source